Application of Adipose-Derived Stem Cells in Treatment of Bone Tissue Defects by Najman, Stevo et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
125,000 140M
TOP 1%154
5,000
1Chapter
Application of Adipose-Derived 
Stem Cells in Treatment of Bone 
Tissue Defects
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Abstract
Despite excellent self-regeneration capacity of bone tissue, there are some large 
bone defects that cannot be healed spontaneously. Numerous literature data in the 
field of cell-based bone tissue engineering showed that adipose-derived stem cells 
(ADSCs) after isolation could be subsequently applied in a one-step approach for 
treatment of bone defect, without previous in vitro expansion and osteoinduction. 
However, standard approaches usually involve in vitro expansion and osteoin-
duction of ADSCs as an additional preparation step before its final application. 
Bioreactors are also used for the preparation of ADSC-based graft prior application. 
The commonly used approaches are reviewed, and their outcomes, advantages, dis-
advantages, as well as their potential for successful application in the treatment of 
bone defects are discussed. Difficulty in spontaneous healing of bone defects is very 
often due to poor vascularization. To overcome this problem, numerous methods 
in bone tissue engineering (BTE) were developed. We focused on freshly isolated 
stromal vascular fraction (SVF) cells and ADSCs in vitro induced into endothelial 
cells (ECs) as cells with vasculogenic capacity for the further application in bone 
defect treatment. We have reviewed orthotopic and ectopic models in BTE that 
include the application of SVFs or ADSCs in vitro induced into ECs, with special 
reference to co-cultivation.
Keywords: stromal vascular fraction, adipose-derived stem cells, endothelial cells, 
in vitro-induced differentiation, bone tissue engineering, vascularization, osteogenic 
process stromal vascular fraction, adipose-derived stem cells, endothelial cells, in 
vitro-induced differentiation, bone tissue engineering, vascularization, osteogenic 
process
1. Introduction
Structure of the bone tissue is very dynamic due to environmental influence but 
also because of many factors that act inside the body [1]. The bone can regenerate 
and repair itself, but large fractures and bone defects fail to heal and repair success-
fully. In addition to other adverse factors, this results in delayed unions, malunions, 
or nonunions. To aid bone healing and repair in such situations, build bone-defi-
cient areas, or replace missing bone as well as in purposes of joint reconstruction, 
bone grafting is used [2–5].
Bone grafting is one of the most common options for the treatment of major 
bone defects, and the use of bone grafts is among the most common procedures 
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in orthopedic surgery and the second most frequent transplantation of tissue 
after blood. Over 2 million bone grafting procedures are performed annually in 
surgery [5, 6]. Bone graft material, alone or in combination with other materials, 
can perform bone healing function by having at least one of the features among 
osteogenicity, osteoinduction, and osteoconduction and therefore usually have one 
or more components—scaffold, as an osteoconductive matrix that supports bone 
growth, osteoinductive proteins and factors, and osteogenic cells [5, 7]. The main 
types of bone grafting materials are autografts, allografts, xenografts, synthetic 
and biological tissue engineering biomaterials, and combinations of these materials 
[2–6]. Bone grafts and graft substitutes may differ by material type, source, and ori-
gin and may also be categorized as osteogenic, osteoinductive, and osteoconductive 
agents [7]. The choice of bone graft depends on the condition of the bone tissue, 
defect size, surgical feasibility of the procedure, possible health complications, graft 
structure, its biological and mechanical characteristics, size and shape, cost, and 
ethical issues [5].
Each of the bone graft material and its substituents has its advantages and disad-
vantages, of which there is considerable agreement in surgical practice. Autografts 
are the best clinical solution among grafts because they have all the necessary proper-
ties to stimulate bone repair and regeneration—osteogenicity, osteoinductivity, and 
osteoconductivity—as they provide osteogenic cells, osteoinductive factors, and 
osteoconductive scaffold for bone growth. So far, autografts have proven superior in 
quality and time to bone healing. That is why in orthopedic practice, for the purpose 
of reconstruction of small defects and replacement of lost bone, autografts are the 
“gold standard” [3, 5–7]. Autografts can be of different types such as vascularized 
grafts, bone tissue, or bone marrow. They are usually obtained from the iliac crest, 
as well as from mandibular bone in dentistry, and by osteectomy and osteoplasty in 
various procedures. The vascularized fibula is used for the treatment of congenital 
bone damage, replacement of the bone segment after trauma, and in the case of a 
malignant tumor so that the periosteum and nutrient artery allow the graft to live 
and grow in the transplanted site [4, 8, 9]. The use of autografts often involves addi-
tional surgery and additional pain, and there is a frequent occurrence of morbidity at 
the donor site, which with limited availability is a limitation to their use. Morbidity, 
although low, is significant and ranges from minor to major complications, and there 
is a risk of injury to large blood vessels and visceral organs while taking the graft. The 
type of complications and their severity depends on the donor site as well as whether 
the graft material is taken at the same incision on the primary surgical site [2, 3, 5–8].
Allografts are much more available for orthopedic purposes. They have an osteo-
conductivity property, they can be well remodeled, but they are poorly osteoinduc-
tive, which can be present if they have an organic matrix. All of these properties 
depend on the size of the graft and the grafting site [3–6, 8]. Allografts are obtained 
from a bone bank containing cadaveric bones and can be found in various forms. 
Compared to autografts, allografts lack osteogenic properties and thus have an 
overall weaker bone regenerative potential, and their integration into the recipi-
ent bone over the long term may be insufficient. Allografts can induce immune 
response and rejection and requires caution because of the possibility of transmis-
sion of pathogens from the donor organism, and their disadvantages are also high 
costs and lack of availability of donors [3, 5–8]. To reduce some disadvantages and 
limitations by allografts, cells and proteins that can elicit an immune response can 
be removed, thereby also reducing the possibility of transmission of viral infec-
tion by donors. Usually, the sterilization and deactivation process of the proteins is 
performed before the use of the allograft, but then they lack osteoinductive factors, 
which in turn remain if the demineralized bone matrix is prepared [4, 8].
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Xenografts are obtained from species other than humans, e.g., bovine bone, 
which is much used in dentistry. There are also nonbone xenograft materials such as 
sclera, collagen membranes, and coral-derived materials. Compared to autografts, 
xenografts as allografts only have osteoconductive and osteoinductive but lack 
osteogenic features. There is a risk of zoonotic transmission in xenografts treat-
ment, and rejection is more likely and stronger than in the case of an allograft. 
Xenografts are cheaper, but the results of their application are inconsistent [4–6].
In addition to bone grafts (autograft, allograft, xenograft), newer bone sub-
stitutes are the ceramic types (calcium compounds: hydroxyapatite, tricalcium 
phosphate (TCP), calcium sulfate) and biological factors such as growth factors 
and others (bone morphogenetic proteins (BMPs), platelet-rich plasma (PRP), 
demineralized bone matrix (DBM)). Bone substitutes have been used for decades 
and have been defined as synthetic, inorganic, or organic, as well as biological 
origin materials, or a combination of those used to treat bone defect instead of 
bone [3, 4, 6]. Bone substitutes are especially used in traumatology and oncologic, 
spine, and prosthetic surgeries. Suitable bone substitutes should be biocompatible, 
not provoking an adverse inflammatory response, osteoinductive, osteoconduc-
tive, resorbable, easily molded into the bone defect, nonconductive, sterilizable, 
available, traceable in vivo, and at a reasonable cost [6]. The integration of bone 
substitutes over the long term may not be sufficient. Bone substitute materials of a 
synthetic nature such as calcium phosphate (CaP)-based biomaterials often behave 
osteoconductively only and can be remodeled. Osteoinductivity is possessed by 
biological factors such as bone matrix proteins or BMP-type growth factors that 
can be added to other bone substitutes [3, 8]. Ceramic-based bone graft substitutes 
include hydroxyapatite (HA), TCP, calcium sulfate, and bioglass used alone or in 
combination. Ceramics can be used in the form of granules, blocks, or moldable 
paste shape, and the occurrence of injectable cements was particularly significant 
because it enabled a mininvasive application [6, 7, 10]. Calcium phosphate-based 
bone substitutes have wide clinical use, since they are generally therapeutically 
effective, although they have poor mechanical properties, are less strong than bone 
tissue, and can be completely resorbed. The more advanced variants of HAs have 
biomimetic properties, since they include ions (carbonates, Mg, fluoride, Sr), so 
that natural HA is imitated [6]. Polymer-based bone substitutes can be degradable 
and nondegradable polymers and are applied alone, as co-polymers, or in combina-
tion with other materials [7, 10]. Various marine biomaterials are also used as bone 
substitutes, including chitosan, corals, and sponge skeleton [7]. Although biologi-
cal factors generally influence good bone formation, the clinical application is not 
widespread due to high prices and possible adverse side effects [3]. Growth factors 
as bone substitutes, such as BMPs, transforming growth factor-beta (TGF-beta), 
platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF), can 
be natural and recombinant and can be used alone or in combination with other 
materials [7]. BMPs are bone growth factors that are widely used in spine surgery 
and for the treatment of tibial nonunion. The efficiency of some biological factors, 
as is the case with the PRP and DBM, is still an open question [6, 10].
The shortcomings in the outcomes of bone healing were the impetus to 
seek new types of grafts and bone substitutes. On these motives, a bone tissue 
engineering (BTE) as a new field began to develop in the last decades of the last 
century, integrating multiple disciplines such as cell biology, developmental and 
molecular biology, biomechanics, biomaterials science, immunology, and others. 
With the progressive introduction of innovations and new technologies, BTE has 
been offering more and more solutions to reduce the disadvantages of traditional 
bone grafts and improve the process of healing fractures and defects by achieving 
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better graft incorporation, osteoconductivity, osteoinductivity, and osteogenicity 
[5, 9–11]. Combining tissue scaffolds, growth factors, cells (especially stem cells), 
and gene therapies, along with three-dimensional printing and other new techno-
logical products, makes BTE a promising option. BTE has progressed over time, 
producing grafts with increasing ability to regenerate and repair bone [5–7, 9–12]. 
Cell-based treatment is emerging as a more promising approach in regenerative 
medicine. Cells (e.g., osteogenic or mesenchymal stem cells and others) are used 
to create new bone alone or are seeded onto a support matrix or scaffold to form 
bone tissue in vitro [6, 7, 9, 10, 13]. On these principles, engineered vascularized 
bone grafts can be created with some similarities to autografts [9, 10, 14]. Of 
particular interest in BTE is the application of mesenchymal stem cells because of 
their multipotency and the presence of osteogenic potential [6, 9, 10, 13, 15]. Cells 
can also be used as a vehicle for osteoinductive genes [6, 10]. Recent developments 
include ex vivo bioreactors capable at the very automated and controlled way 
to imitate in vivo environment producing bone with appropriate biomechani-
cal properties before implantation [7, 9, 10, 12, 13]. To test the new features and 
products of BTE, as well as preclinical testing, many in vitro and in vivo methods 
and models have been developed with various advantages and disadvantages 
respectively [11, 16].
2. Sources of cells for tissue-engineered grafts
Nowadays, adult stem cells can be purified from different adult tissues and used 
in BTE as potential progenitors of osteogenic cells. It is reported that stem cells 
intended for BTE can be derived from many different tissues such as bone marrow, 
umbilical cord, dental pulp, as well as adipose tissue [18]. For instance, mesenchy-
mal stem cells (MSCs) derived from bone marrow can be successfully differenti-
ated into cells of various connective tissues [19] as well as in bone cells which give 
opportunity for its implementation in cell-based BTE [10, 20]. Despite its frequent 
use in BTE, bone marrow MSCs are reported to have some disadvantages, espe-
cially low cell quantity at isolation [21]. This is also an unfavorable characteristic 
for many other adult stem cells which imply in vitro cell expansion after their 
isolation in order to obtain sufficient quantity of cells which is mandatory for its 
further implementation in cell-based BTE. Morbidity and pain are also reported as 
accompanying side effects that are consequences of bone marrow MSC harvesting 
[21]. Nevertheless, MSCs are easier to isolate from accessible adipose tissue, which 
can be harvested with minimally harmful [22] and less painful methods. These 
multipotent cells derived from adipose tissue were reported by Zuk et al. [23] and 
suggested as a possible alternative to bone marrow MSCs [23]. Others also reported 
that stromal cells derived from adipose tissue rapidly proliferate and can be 
obtained in sufficient quantity, eliminating the need for in vitro expansion [24, 25] 
which is a tremendous advantage of adipose-derived stem cells (ADSCs) over other 
tissues that are potential sources of adult stem cells. The more recent study showed 
that bone morphogenic protein 2-transduced human adipose-derived MSCs had 
higher capacity for osteogenic differentiation than bone morphogenic protein 
2-transduced MSCs from bone marrow [26]. With all this advantages, MSCs from 
adipose tissue are also reported to have similar potential to differentiate toward 
osteoblast and form bone as bone marrow MSCs [27]. Adipose tissue therefore 
represents a reliable source of adult stem cells intended for therapeutic purposes in 
BTE. In addition to this, in the past decade, we are witnessing an increase of inter-
est for application of ADSCs in cell-based BTE.
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2.1 Adipose-derived stem cells
The capacity to differentiate toward a broad spectrum of specialized cells 
such as bone cells, cartilage cells, muscle cells, endothelial cells, liver cells, neural 
cells, and others [18, 22, 28] makes ADSCs suitable generally for cell-based tissue 
engineering as well as for BTE. ADSCs represent a form of MSCs [29] that could be 
simply isolated from both subcutaneous and visceral adipose tissue that are usually 
sufficiently abundant in almost every individual. Nevertheless, it is reported that 
ADSCs derived from visceral fat have higher osteogenic potential than ADSCs from 
subcutaneous fat in rabbits [30] which should be taken into consideration when 
selecting the type of adipose tissue as starting source for ADSC isolation. Adipose 
tissue in humans could be obtained by liposuction or resection method that are both 
reported to yield similar quantity and good quality of MSCs [31]. More precisely, 
a direct source of ADSCs is stromal vascular fraction (SVF) which is obtained by 
enzymatic digestion of previously isolated fat tissue and its subsequent centrifuga-
tion [15]. There are well-described markers intended for ADSC characterization. 
Particularly, ADSCs are reported to have recognizable fibroblast-like, spindle-
shaped morphology [23, 27], good longevity and plastic adhesion properties in 
in vitro condition [32], and capacity for rapid proliferation in cell culture [24, 33]. 
ADSCs also have characteristic expression pattern of CD cell surface markers. In 
general, there is an accordance in literature about the expression pattern of CD 
markers which should be used for ADSC characterization. For instance, Cai et al. 
[28] summarized that some characteristic CDs, particularly CD166, CD105, CD90, 
CD73, CD44, CD29, and CD13, have high expression in adipose-derived stem 
cells [28] which is in accordance with other reviews [34]. Also, according to Bajek 
et al. (2016) high expressions of CD73, CD44, CD105 and CD90 are indications 
mainly used for adipose-derived stem cell identification [35]. Therefore, before 
further steps in their application and analyses, it is very important to examine and 
determine expression of CDs and other markers like cell morphology in order to 
characterize ADSCs.
3. Bone substitutes and regulatory factors
As it is mentioned in the previous text, apart from cells, there are two more 
components in cell-based BTE, and those are bone substitute materials and regula-
tory factors. These three components together, combined in appropriate manner, 
makes specific construct which is an adequate alternative to bone grafts for the 
treatment of bone tissue defects. Bone substitutes are used as appropriate scaffolds 
for osteogenic cells. Chao et al. [12] described scaffold as logistic templates for 
guided formation of tissue [12]. Three-dimensional scaffolds that support osteo-
genic differentiation of the stem cells are seen as crucial components for in vitro 
engineering of bone construct which can be clinically usable [9]. Even more, to 
respond to special requirements at the defect site, engineering of the customized 
bone grafts was also proposed [36]. Bone substitute materials provide appropri-
ate microenvironment for differentiation and proliferation of bone cells [37], and 
porosity, particle size, and material composition also play important roles [38]. At 
the first place, bone substitutes should be biocompatible which, among the other 
things, implies that they are non-toxic and non-genotoxic [39]. Biomaterials are also 
used to fill defects and compensate lost part of bone tissue at the defect site. Bone 
substitutes that belong to a group of bioactive biomaterials are capable for interac-
tion with the biological environment and can provide conditions for cellular actions 
Clinical Implementation of Bone Regeneration and Maintenance
6
[40] which is of benefit for bone regeneration. Nowadays, many different synthetic 
and natural bone substitutes are reported to be in use [10, 40, 41]. Particularly, 
materials based on hydroxyapatite and β-tricalcium phosphate are suitable for 
BTE [42]. In addition, materials based on bone mineral matrix are frequently used 
[43–46]. Also, regulatory factors are not less important components in BTE, and at 
the first place, they should induce and support osteogenic differentiation, adhesion, 
and proliferation of implanted cells. Because of its significant properties, here the 
focus will be on platelet-rich plasma as a source of regulatory factors for cell-based 
BTE. PRP is one of the well-known natural sources of different stimulative regula-
tory factors [47–49]. Last decade, PRPs are constantly drawing attention of many 
researchers in fields of regenerative biology as well as in BTE. That is reasonable 
because regulatory factors from PRP is reported to enhance adhesion, differentia-
tion, and proliferation of the cells and also enhance angiogenesis [47, 50] which may 
support regeneration and reparation of bone tissue. In addition, it was reported that 
regulatory factors from PRP can enhance osteogenic process by inducing prolifera-
tion and differentiation of MSCs [51, 52]. Nevertheless, the question about adequate 
and stimulating concentration of platelets in prepared PRP is of great importance, 
and it is still topical. The opinions about adequate concentration of platelets in PRP 
intended for BTE are different. There are reports that higher platelet concentrations 
might have an inhibitory effect [53], and on the other hand, concentrations that 
are lower than the physiological level is reported to be useful for bone regeneration 
[54]. Finally, there is a recommendation that optimal concentration of platelets in 
PRP intended for bone treatment should be from four to eight folds higher than 
the normal physiological level of platelets in the blood [47]. Another advantage of 
activated PRP is that it can form fibrin fibers which can couple ADSCs with bone 
substitute material and improve retention of all construct components [55, 56] 
similar to reports where fibrin was used for this purpose [57, 58]. Finally, there is a 
growing interest about synergistic effects of ADSCs and PRP for bone regeneration. 
Many studies reported promising osteogenic potential of ADSCs and PRP combina-
tion [46, 55, 56, 59] and stimulative potential of PRP that improves osteogenesis 
in combination with cells [51, 60]. In addition, Fernandes and Yang [49] reviewed 
and summarized some recently published data which implies that adipose-derived 
stem cells obtained from human, mouse, rat and rabbit in combination with PRP in 
in vitro and/or in vivo conditions are related with outcomes which are of benefit for 
BTE [49].
4. Approaches in application of ADSCs in cell-based BTE
4.1 One-step versus multistep approaches
Numerous literature data in the past decade are related with extensive stud-
ies about regenerative potential of adipose-derived stem cells. It is well-known 
that ADSCs in combination with bone substitute materials and regulatory factors 
possess certain osteogenic potential that can initiate and boost osteogenic process 
both in orthotopic and ectopic conditions. Recent studies showed that good yield of 
ADSCs after isolation from adipose tissue provides opportunity for its subsequent 
application in one-step approach in cell-based bone tissue engineering without 
previous in vitro expansion and differentiation. Nevertheless, standard approach 
in cell-based BTE usually involves in vitro pretreatment of ADSCs as an additional 
step before its final application in order to induce differentiation of ADSCs into 
osteogenic cells. Literature data showed that both approaches are promising 
for implementation in treatment of bone tissue defects. Our experience about 
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osteogenic capacity of differently prepared ADSCs is mostly in accordance with 
other related studies. Based on our previously performed experimental studies and 
published results, these two approaches have quite different outcomes, and each 
approach has its advantages and potential to be successfully applied in treatment 
of bone tissue defects. Also, there is a growing number of researches that employed 
bioreactors for bone graft engineering.
There are well-described methods for ADSC preparation prior their applica-
tion in BTE. Without purification, in vitro expansion, and osteoinduction, ADSCs 
contained in freshly isolated adipose-derived SVF could be prepared and applied 
in just one step which is described as intraoperative approach [57, 58, 61] or one-
step procedure [62]. Intraoperative approach implies construct assembling during 
surgical procedure [13] by combining cells, bone substitutes, and regulatory factors 
together in one construct. One of the earlier reports by Aslan et al. [63] presented 
usage of noncultured human MSCs isolated from bone marrow [63]. More recently 
published articles demonstrated intraoperative application of freshly isolated 
SVF cells from human adipose tissue [57, 58] and freshly isolated adipose-derived 
SVF cells from mice epididymal adipose tissue in ectopic bone-forming model 
[56]. One-step surgical procedure is also used in oral and maxillofacial surgery 
for maxillary sinus floor elevation [38, 64]. All these studies suggest that previous 
in vitro pretreatment of ADSCs and their separation from SVF population prior 
their implementation in BTE is not necessary. Good yield of ADSCs enables bypass-
ing of in vitro expansion step which goes in favor of the one-step concept in BTE. In 
addition, the autotransplantation of freshly isolated ADSCs for the treatment of 
bone tissue defects also enables avoiding problems with immune response [61] that 
might occur in allotransplantations and xenotransplantations. Adipose-derived SVF 
is reported to have great capacity for regeneration processes thanks to its hetero-
geneity [29] because it is composed of different cell types and growth factors [15], 
especially with cells that have osteogenic and angiogenic potential [38] which is of 
great importance for treatment of bone defects (Figure 1).
Also, it is reported that the entire procedure can be finished in a few hours 
[13, 57, 65] which reduces wait time for surgery [61] and is one of the major 
advantages of this approach. In addition, Jurgens et al. [62] showed that ADSCs 
can adhere promptly onto materials collagen type I/III and poly(L-lactide-co-
caprolactone); particularly it is reported that nearly 10 minutes is sufficient time 
for ADSC adhesion [62] that significantly reduces time needed for construct 
preparation.
On the other hand, there are many well-described approaches which involve 
several steps for in vitro expansion and osteogenic differentiation of ADSCs before 
its final application [27, 46, 66]. In these approaches, by in vitro cultivation, ADSCs 
are additionally expanded and purified from heterogenous SVF [33] that are directly 
derived from adipose tissue (Figure 1). After that step, purified ADSCs are sub-
jected to in vitro induction in osteogenic media to differentiate toward osteogenic 
cells before further application which follows in the next step. The characteris-
tic components of osteogenic medium are dexamethasone, ascorbic acid, and 
β-glycerophosphate [32, 34, 67] which are frequently used for ADSC osteoinduction 
[68]. There are different data about the duration of in vitro osteogenic induction 
needed for ADSC differentiation toward osteogenic cells, but literature data mostly 
referred to 2 weeks [23, 34, 67, 69, 70] or between 2 and 3 weeks [22] (Figure 2). 
It was summarized that during osteogenic differentiation, ADSCs start expression 
of lineage-specific genes for osteogenesis such as osteocalcin, transcription factor 
osterix, transcription factor Runx2, bone sialoprotein, alkaline phosphatase, and 
others [33, 41] which might be detected by gene expression analysis [62] as confirma-
tion of successful osteogenic differentiation of ADSCs. For instance, Cvetković et al. 
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[46] recently published that bone-related genes osteocalcin, transcription factor 
osterix, alkaline phosphatase, and collagen I alpha1 chain had the highest expres-
sion in in vitro osteoinduced ADSCs at 15th day of osteoinduction [46]. Also, it is 
reported that changes in cell morphology during osteogenic induction to a more 
cuboidal shape could be observed in ADSC culture [70]. The presence of mineraliza-
tion signs and proliferation of the ADSCs are also reported as markers of osteogenic 
differentiation during in vitro osteoinduction [17, 66, 70]. Particularly, after in vitro 
osteogenic differentiation, mineralization of the cell matrix could be evaluated using 
Von Kossa and alizarin red staining [32, 67]. In the next step, when osteoinduction 
Figure 1. 
Expansion and purification of ADSCs from adipose-derived SVF through in vitro cultivation. (a) Adipose-
derived SVF 24 h after isolation; (b) adipose-derived SVF 72 h after isolation; (c) adipose-derived SVF 7 days 
after isolation; and (d) ADSCs the first day after the first passage. Black arrows show ADSCs. Magnification 
100×.
Figure 2. 
In vitro osteoinduction of ADSCs. (a) ADSCs 3 days after cultivation in osteogenic media; (b) ADSCs 2 weeks 
after cultivation in osteogenic media. Black arrows show ADSCs. Magnification 100×.
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is confirmed, osteoinduced ADSCs are seeded on bone substitute material and 
supplemented with regulatory factors prior using in BTE. There are examples where 
prepared constructs, after ADSCs seeding on biomaterial (i.e. bone substitute mate-
rial), are subjected to in vitro osteoinduction before implantation [27] which requires 
additional time for construct preparation and delays final application. Overall, 
in vitro osteoinduction is proven to be an effective method for preparation of the 
ADSCs, and that is confirmed in many different studies [27, 46, 66] which makes this 
method suitable for BTE. But methods that consider at least two steps usually few 
weeks for performing and additional material for preparation of ADSCs are time- 
and money-consuming and more complicated to perform than the one-step method.
According to literature data, both in vitro osteoinduced ADSCs and untreated 
freshly isolated ADSCs are capable to induce osteogenesis to some level in ortho-
topic as well as in ectopic conditions. However, there are differences in their capac-
ity to initiate and maintain osteogenic process. By comparing our two recently 
published studies, it could be concluded that ADSCs prepared and utilized in 
different manners induced different expression patterns of analyzed osteogenic 
markers in ectopic implants [46, 56]. In one of the studies, it was shown that 
untreated ADSCs contained in freshly isolated SVF are capable to quickly initiate 
osteogenic process, but between the 4th and 8th week of implantation, decreasing 
bone-related gene expression was detected [56]. On the other hand, Cvetković 
et al. [46] reported that in vitro osteoinduced ADSCs cause steady osteogenesis 
with peak at the 8th week [46]. In addition, there is a study which confirmed that 
osteogenically differentiated human ADSCs induced forming of bone tissue after 
8 weeks in ectopic condition [27]; thus the application of osteoinduced ADSCs 
seems to have a favorable effect on osteogenesis. In other words, all these findings 
indicate that freshly isolated untreated ADSCs cannot maintain osteogenesis in 
ectopic condition to that extent as in vitro osteoinduced ADSCs can do. Previous 
osteoinduction triggered differentiation of ADSCs toward osteogenic cells which 
had sufficient potential to start and maintain osteogenesis for a longer period [46]. 
It was concluded that one of the reasons why untreated ADSCs within SVF failed 
to maintain osteogenic process for a longer period may be because of the lack of 
osteogenic factors in the ectopic environment which was used as model in this study 
[56]. Bone tissue normally had factors such as cytokines, mechanotransduction, 
and closeness of osteoprogenitor cells that are reported to act stimulative in bone 
formation, but they are reduced in ectopic bone-forming models [71]. Therefore, 
these factors are characteristic only for orthotopic models which allow evaluation 
of osteogenic potential of examined engineered construct in real natural milieu 
of the bone tissue. For that purpose the frequently used orthotopic models in BTE 
are critical-sized defects in calvaria bone [24] and long bones [45, 72, 73] where 
large rodents and other mammals are suitable. In addition, it was reported that the 
presence of sufficient doses of osteogenic factors are needed to support osteogenic 
differentiation of implanted cells and bone formation in ectopic conditions [57, 65].
Deficiency of osteogenic factors in ectopic models may be bypassed to some 
extent by addition of stimulating factors to ADSCs such as activated PRP. The 
addition of activated PRP can make microenvironmental conditions similar to the 
natural ones that occur during bone trauma. But it is known that platelets release a 
major portion of regulatory factors immediately after injury [74], which might be 
sufficient to stimulate ADSCs immediately after its implantation but definitely not 
for a longer period. The manner and applied doses of PRP obviously was enough 
to support development and maintenance of osteogenesis guided by previously 
in vitro osteoinduced ADSCs [46] and was not sufficient to support maintenance 
of osteogenic process guided by untreated ADSCs within SVF [56]. Regarding the 
short period of efficient action of PRP, Fernandes and Yang [49] reported that 
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there is a need for carrier that would deliver PRP in the manner that it can act more 
efficiently and release growth factors sustainably [49]. This might be the key for 
enhancing osteogenesis guided by freshly isolated and untreated ADSCs within 
SVF. Despite disadvantages of ectopic models, there are many literature data where 
ectopic subcutaneous implantations were conducted [43, 44, 71, 75, 76] because 
they allow examining the real potential of the implanted cells [65] alone and with-
out the impact of the factors that are normally present in bone tissue. Therefore, 
selection of adequate animal model should depend on experimental goal, and 
finally it is important for interpretation and extrapolation of obtained results [1]. 
Nevertheless, osteogenic capacity of previously discussed combinations of differ-
ently prepared ADSCs should be evaluated in orthotopic bone-forming models 
because they are closer to real situations where treatment of bone defect is needed. 
That is especially of great importance for intraoperative (one-step) method because 
it is still unclear if this method ready for clinical implementation. In addition, 
recently a safe and feasible one-step surgical procedure for maxillary sinus floor 
elevation with implants consisting of calcium phosphate and freshly isolated SVF 
was demonstrated [64].
Preparation and utilization of freshly isolated and untreated ADSCs at the first 
place provides tremendous acceleration of procedure performance which is very 
important especially in everyday clinical practice where intraoperative method 
is desirable. Despite much longer period which is needed for ADSC preparation 
and utilization, there is no doubt that osteoinduction is a reliable method for 
the purposes of BTE. Overall, according to studies published so far [46, 56] that 
are mostly in accordance with other related studies, it could be concluded that 
untreated ADSCs contained in freshly isolated SVF have different potential from 
in vitro osteoinduced ADSCs to start and maintain osteogenic process which leads 
to quite different outcomes, at least in ectopic condition. Surely, each of presented 
approaches has its own advantages and potential to be successfully applied in treat-
ment of bone tissue defects. We believe that both approaches could be successfully 
utilized in the treatment of bone tissue defects, but additional research should be 
conducted especially in orthotopic models in order to determine required doses of 
osteogenic factors needed to support osteogenic process.
4.2 ADSCs-based grafts prepared in bioreactors
We previously discuss some methods for ex vivo engineering of the grafts in 
in vitro static condition using cells and bone substitutes as scaffold. The advanced 
method for graft engineering involves the use of bioreactors. Bioreactors are 
defined as devices for precise monitoring and controlling of conditions which are 
necessary for biological and biochemical processes [77]. The controlling and moni-
toring of the conditions are in favor of minimalizing variability of graft production 
as well as standardization of the process [13] for graft engineering. Amini et al. [10] 
reviewed several types of bioreactors which include perfusion bioreactors, rotating 
bioreactors, and spinner flask bioreactors. Perfusion-based bioreactors, which are 
marked as mostly used, significantly stimulate osteogenic cells due to fluid flow 
[10]. Thus, the dynamic conditions, which bioreactors provide, are more similar to 
in vivo conditions which allow proliferation and differentiation of seeded cells of 
three-dimensional scaffolds in a much appropriate way than static in vitro condi-
tions. There is literature evidence where human ADSCs were successfully used for 
engineering bone grafts in stirrer flask bioreactors [78] as well as viable bone tissue 
construct in perfusion bioreactor [79]. However, the engineering of the ready-to-
use bone grafts using bioreactors could last for weeks, and it must be performed 
in several steps. Also, bioreactor devices for BTE purposes have high prizes, and 
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the whole procedure is not economical because it requires a higher consumption of 
medium and other materials which reduces accessibility of this method.
5.  Solving vascularization problems in bone tissue engineering by SVF 
and ADSCs in vitro induced into endothelial cells
5.1 The problem of insufficient vascularization in bone tissue engineering
Bone tissue is a self-renewable tissue with an excellent regeneration capacity [80]. 
Some bone fractures, tumors, or bone loss can cause such large bone deficiencies 
that cannot be healed spontaneously [80], since their size goes beyond bone self-
renewing capacity [81]. In those cases, classical surgical procedures or bone tissue 
engineering strategies must be applied [82]. The main problem that has not yet been 
completely overcome is insufficient vascularization in critical-sized bone defects. 
Therefore, a perfect bone substitute must have excellent angiogenic features [83].
Until now, various BTE methods for resolving insufficient vascularization were 
performed: changing the architecture and interconnectivity of pores of the applied 
biomaterial [84], co-cultivation of different types of cells [85], using mechanical 
stimulation [86], and adding one [87] or a couple of growth factors in the implants 
at the same time [88]. The implants were placed into highly vascularized areas or, 
before the implantation procedure, seeded with cells that secrete chemoattractants 
for attraction of the host’s cells and blood vessels with small diameter [89]. Also, 
microvascular fragments of adipose tissue were incorporated [90], and tissue flap 
procedures [91] and scaffolds made of nano- or microfibers were applied [92].
One of the possible methods to facilitate anastomosing between the bioengi-
neered vascular structures with the ones from the surrounding tissue is the con-
struction of prevascularized scaffolds that contain endothelial cells (ECs) [93]. ECs 
constitute a continuous monolayer among interstitial fluid and blood and have cru-
cial importance in vascularization and in controlling the function of blood vessels 
[94]. By producing, metabolizing, and releasing numerous humoral and hormonal 
agents, these cells create an active antithrombotic surface in order to ease transit of 
plasma and cell components through the blood vessels [94]. Nevertheless, not only 
that ECs are important for successful developing of the functional vascular system, 
other cells that constitute blood vessel wall, smooth muscle cells, and perycites are 
also of great importance [9]. Mural precursor cells participate in vascular remodel-
ing and contribute to better vascularization in cell cultures which is the reason why 
these cells are desirable as one of the cell lines in co-culture [95, 96].
An important question regarding the use of ECs, not only in BTE but in tissue 
engineering generally, is “which type of ECs should be used?” [97]. Sources of 
autologous ECs are limited [98], and mature ECs have limited proliferative capacity 
[99, 100]. In addition, the procedure of isolation is invasive, it is hard to collect a 
plentiful number of cells, and there is a possibility of contamination, infection, and 
change of phenotype and function of ECs during in vitro cultivation [94, 99, 101]. 
Also, ECs isolated from different organs manifest different phenotypes in vivo, 
which mean that EC types for the application in tissue engineering should not be 
selected randomly [102].
Bearing all this in mind, alternative methods have been developed in order to 
obtain more stable sources of ECs. These methods include in vitro induction of 
MSCs into ECs. An easily accessible tissue [103] that attracts a great attention in the 
last few decades is adipose tissue. Primarily cell components of adipose tissue are 
cells filled with lipids—adipocytes. Besides adipocytes, stromal vascular fraction of 
adipose tissue consists of microvascular ECs, pericytes, fibroblasts, macrophages, 
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leukocytes, pre-adipocytes, mastocytes, and adipose-derived mesenchymal stem 
[104, 105]. SVF with heterogeneous cell populations can be obtained upon simple 
enzyme-based adipose tissue isolation procedure that includes enzymatic diges-
tion, filtration, and centrifugation [76, 106, 118, 128, 129]. After this procedure, 
SVF can be used as a source of ADSCs directly [128] or after expansion in cell 
culture through few passages [104] and subjecting to differentiation toward certain 
cell line [67, 76, 105, 107, 108, 129].
ADSCs secrete numerous angiogenesis-related mediators including vascular 
endothelial growth factor (VEGF), bone morphogenic proteins, placental growth 
factor (PGF), angiopoietin-1, hepatocyte growth factor (HGF), transforming 
growth factor-β, and fibroblast growth factor 2 (FGF-2) [109]. Secretion of these 
angiogenic factors makes ADSCs convenient for regenerative cell therapy [106]. 
Among the abovementioned growth factors, VEGF and BMP2 are considered to 
be the main factors during bone regeneration, VEGF on the vascular and BMP2 on 
the osteogenic side [110]. Besides soluble growth factors, ADSCs release plasma 
membrane-derived vesicles (MVs) that can contain some pro-angiogenic and 
osteogenic molecules [111] with an influence on adjacent cells. In addition, growth 
factors and other molecules contained within MVs (cytokines, RNAs, microRNAs) 
can be transported to some more distant target cells all over the body. By taking up 
the content of MVs, target cells use these molecules and perform certain biological 
activity including angiogenesis of target cells which is of crucial importance in bone 
tissue regeneration [112].
In order to apply SVF as a source of cells with vasculogenic capacity in bone 
tissue engineering, several methods have been described. These methods include 
application of SVFs immediately after isolation from adipose tissue as well as after 
in vitro induction of endothelial differentiation.
5.2  Potential of stromal vascular fraction as a source of cells with vasculogenic 
capacity for application in bone tissue engineering
Freshly isolated SVF contains both endothelial and skeletal progenitor cells [113]. 
This property was widely used to construct osteogenic and vasculogenic grafts. It has 
been found that three-dimensional (3D) cultures of ECs and osteoblasts (OBs) as well 
as osteogenic-vasculogenic constructs could be achieved by using perfusion-based 
bioreactor system of single cell source human SVFs in ceramic scaffolds [113]. Namely, 
SVFs were seeded on 3D porous ceramic scaffolds and cultivated during 5 days using 
bioreactor system. Eight weeks after implantation of resulting scaffolds in nude 
mice, formation of functional vascular network that was connected with the host’s 
vasculature as well as ectopic bone formation was observed. Nude mice model was 
also used by Todorov and his colleagues [114]. This team isolated SVFs from human 
abdominal lipoaspirates and obtained hypertrophic cartilage (HC) pellets from 
bone marrow-derived stromal cells. Devitalized HC was embedded in fibrin gel and 
implanted with and without SVFs ectopically and in calvarial defects. Twelve weeks 
after implantations, vascularization and bone formation of grafts enriched with SVFs 
were enhanced in ectopic, subcutaneous, and in orthotopic experimental model.
The use of human SVF-derived vascular progenitor cells can speed up the 
engraftment of critical-sized osteogenic constructs which improves in vivo forma-
tion of the bone tissue [115]. Human SVFs have been isolated, seeded, and cultured 
into hydroxyapatite scaffolds. Perfusion bioreactor system was used in order to 
preserve the cells of CD34+/CD31+ endothelial lineage from the SVF. As a result of 
in vitro cultivation, 5 days after seeding, endothelial and mesenchymal progenitors 
from SVF constituted capillary networks that were able to anastomose with the host 
vasculature 7 days after implantation on an ectopic nude rat model [115].
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With an aim to simulate an intraoperative procedure on an ectopic bone forming 
model, autologous SVFs isolated from epididymal adipose tissue of Balb/c mice and 
platelet-rich plasma were added to the bone mineral matrix (BMM) [128]. BMM 
served as a carrier for cells and growth factors. The constructs were implanted 
subcutaneously, and osteogenic capacity of this combination was examined. Eight 
weeks after implantations, these implants had significantly higher percentage of 
infiltrated tissue and percentage of vascularization than the control (BMM-only 
implants). According to osteogenesis-related gene expression analysis, implants 
with SVFs induced rapid onset of osteogenesis process. One of the reasons for 
such results probably lies in the fact that freshly isolated SVFs had upregulated 
expression of endothelial- and osteogenic-related genes which was proved by using 
real-time PCR analysis.
Non-induced ADSCs cultivated in vitro up to the third passage were mixed with 
allogeneic PRP taken from three healthy Wistar rats [116]. ADSCs-PRP constructs 
were implanted into the jaws of rats that had bisphosphonate-related osteonecrosis 
of the jaw. Eight weeks after the treatment, the incidence of osteonecrosis was 
lower, while the degree of bone turnover and number of osteoclasts were higher 
than the experimental groups that were not treated with ADSCs [116]. These data 
could be explained by the fact that PRP release numerous growth factors that can 
fasten both in vitro and in vivo ADSC differentiation without previous addition 
of any other factors inductive toward certain cell line [129]. One of the possible 
mechanisms of synergistic effect of ADSCs and PRP could be ascribed to the release 
of platelet-derived growth factor from PRP. PDGF has an impact on selectable 
expansion and recruitment of non-induced MSCs, as well as on proliferation and 
migration of progenitors of blood vessel wall cells [117]. It also triggers differentia-
tion of MSCs into blood vessel cells [118] and enhances release of extracellular 
vesicles (EVs)—MVs and exosomes from ADSCs which further influence both 
in vitro and in vivo angiogenic process [119].
On an ectopic model, Man and associates [129] pointed out to the effect of 
ADSCs that is similar to the one shown in the abovementioned orthotopic model. 
ADSCs isolated from inguinal rabbit fat pads and mixed with PRP were loaded 
onto alginate microspheres. Well-developed blood vessel network and good bone 
mineralization were observed 3 months after subcutaneous implantations. Opposite 
results were obtained in another research where non-induced ADSCs were seeded 
on poly (D, L-lactide) scaffolds and implanted in the large rat palatal bone defect 
[120]. Bone formation did not occur even 12 weeks after implantations, and the 
defects were filled with dense fibrous tissue. The differences between the outcomes 
of the different studies could be attributed to the fact that adipose tissue was taken 
from the different localizations of the donors’ body. Also, the implant preparation 
was done in a different manner, and different models were chosen for the implanta-
tion procedure.
Adipose tissue can also be used as a source of microvascular fragments (MVF) 
that can be further applied as vascularization units [121]. MVF isolated from CD-1 
mice were incorporated into thermoresponsive hydrogel (TRH), cultivated, and 
used for filling the osteotomy gaps in the femurs of CD-1 mice. Bone healing was 
assessed 14 and 35 days after induction of osteotomy, while non-incorporated MVF 
as well as no material group served as control groups. It was found that TRH is a 
suitable carrier for MVF since vascularization in MVF-loaded TRH was improved in 
comparison to the control groups. In contrast to this finding, bone formation in this 
group was impaired, probably due to low levels of VEGF expression during the early 
stages of bone healing.
Bone substitute biomaterials based on calcium phosphate, including hydroxy-
apatite (HA), β-tricalcium phosphate (β-TCP), and HA/β-TCP combination, are 
Clinical Implementation of Bone Regeneration and Maintenance
14
often used in BTE due to their good biocompatibility and the absence of toxicity 
of their chemical compounds [122]. These materials also have such 3D features 
that allow immediate colonization by MSCs and extensive revascularization [123]. 
For those reasons, Farré-Guasch and his associates used ADSCs-containing SVF 
seeded on calcium-based biomaterials to treat the patients subjected to maxillary 
sinus floor elevation (MSFE)—a surgical procedure that in some patients must 
precede dental implant placement [124]. Autologous SVFs taken from patients were 
seeded on two types of carriers for two different groups of patients: group 1 had 
SVFs seeded on β-tricalcium phosphate, and group 2 had SVFs seeded on biphasic 
calcium phosphate, while the control group had only ceramics, without cells. 
Histomorphometrical analysis and immunohistochemical staining for blood vessel 
markers such as CD34 and alpha-smooth muscle actin revealed higher number of 
blood vessels and immunoexpression of blood vessel markers in both experimental 
than a control group. These results point out pro-angiogenic influence of SVF.
One of the recently published papers regarding pre-vascularization of various 
engineered tissues compares the use of ADSCs as a potential source of cells with 
vasculogenic capacity in combination with different types of gel-based scaffolds 
[125]. ADSCs were isolated from human fat tissue, cultivated, and, after second 
passage, molded in fibrin as well as agarose-collagen gels. After 14 days of incuba-
tion have passed, the gels were analyzed by two-photon laser scanning microscopy. 
Vascularization was achieved in both types of gels which were detected as branched 
networks of tubular vascular structures in both hydrogels. Nevertheless, volume, 
area, and length of vascular structures supported by ADSCs in agarose-collagen 
hydrogels were comparable to human dermal fibroblast control.
5.3  Potential of adipose-derived stem cells in vitro induced into ECs for 
application in bone tissue engineering
5.3.1 Orthotopic model
In order to increase vascularization, ADSCs induced into ECs were applied in 
BTE by using several models, among which orthotopic model is one of the most 
commonly used. Rat ADSCs in vitro induced into ECs during 8 days was used for 
the construction of allografts [126]. The cells were combined with sterilized and 
decellularized banked allografts made of calvaria from earlier sacrificed Lewis rats. 
Allografts were implanted into critical-sized calvarial defects in rats, and 8 weeks 
after the implantation, blood vessel density was increased. As a consequence, 
bone volume was also increased. In parallel, two other types of allografts were 
constructed—allografts seeded with ADSCs induced into OBs and allografts seeded 
with the combination of ADSCs induced into ECs and ADSCs induced into OBs. 
These implants had weaker vascularization and lower bone volume 8 weeks after 
the implantation than the ECs-only allografts.
ADSCs in vitro induced into ECs were also seeded onto poly(D, L-lactide) 
scaffolds and implanted into critical-sized calvarial defects of Lewis rats [107]. 
Scaffolds prevascularized in this manner did not caused an increase in bone forma-
tion by itself, but according to the conclusion of this team, they could possibly be 
used as a source of cells for accomplishing better vascularization and function of 
the existing OBs. On the other hand, the constructs that were constructed out of 
undifferentiated ADSCs or ADSCs induced into OBs had statistically greater bone 
volume than the implants containing ADSCs induced into ECs.
In another study, also performed on critical-sized calvarial defect model of 
Lewis rats, hydroxyapatite/poly(lactide-co-glycolide) [HA-PLG] was used as a 
biomaterial carrier, while adipose tissue was extracted from inguinal fat pads [127]. 
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ADSCs were induced into ECs as well as into OBs. Vascularization and osteogenic 
process were evaluated in the following groups: (I) HA-PLG scaffolds without cells, 
(II) HA-PLG scaffolds seeded with non-induced ADSCs, (III) HA-PLG scaffolds 
seeded with ADSCs induced into ECs, and (IV) HA-PLG scaffolds seeded with 
ADSCs induced into OBs. The highest bone mineral density, bone regeneration, and 
vascular density in regenerated bone were found in group IV, although none of the 
found differences had statistical significance (P > 0.05).
In order to repair critical-sized bone defects in rat femur, ADSCs induced 
into ECs were used for prevascularization of the modified hierarchical meso-
porous bioactive glass (MBG) scaffold with an enhanced compressive strength 
and then combined with ADSCs subjected to osteogenic differentiation [128]. 
Prevascularized MBG carrying ADSCs induced into OBs had more advanced 
angiogenesis both on the surface and in the interior than the non-vascularized 
MBG carrying ADSCs induced into OBs and MBG scaffolds that were not seeded 
with cells. Moreover, the group with prevascularized MBG scaffolds had the high-
est mineral deposition rate postoperatively. These results indicate that time-phase 
sequential utilization of ADSCs on MBG scaffolds is a good strategy for reparation 
of massive bone defects.
5.3.2 Ectopic model
Ectopic models are important in bone tissue engineering since they provide 
reducing external influences and side effects, thus concentrating on intrinsic 
potential of the applied implant components [54] and their interactions [43]. With 
an aim to overcome the problem of inadequate blood vessels development and 
consequent inability of bone tissue regeneration, the influence of ADSCs in vitro 
induced into ECs on vascularization and osteogenic process in ectopic osteogenic 
implants was examined [129]. The implants composed of ADSCs, BMM, and PRP 
and the ones composed of BMM and PRP were subcutaneously implanted into 
BALB/c mice. Endothelial-related gene expression, high percentage of vasculariza-
tion, and VEGFR-2 immunoexpression show that implants enriched with ECs have 
increased vascularization compared to the cell-free implants. This was followed by 
more pronounced signs of osteogenic process in ADSCs-BMM-PRP implants than 
in BMM-PRP implants. By examining endothelial-related gene expression, vascular 
cell adhesion molecule-1 (VCAM-1) and osteopontin immunoexpression, it was 
also shown that the composition of implants based on biological triad (ADSCs 
induced into ECs, PRP and BMM) is more favorable for improving vascularization 
in the ectopic bone-forming model than in the BMM-only implants [76].
Uninduced ADSCs cultivated up to the 12th day after the third passage, com-
bined with PRP and BMM and subcutaneously implanted into BALB/c mice, also 
have vasculogenic potential [129]. However, their vasculogenic potential is lower 
than that of ADSCs in vitro induced into osteogenic cells and implanted in combi-
nation with BMM and PRP. Specifically, relative gene expression analysis of endo-
thelial gene markers Vwf, Egr1, Flt1, and Vcam1 was significantly higher (p < 0.05) 
in the group that contained osteoinduced ADSCs than in the group with uninduced 
ADSCs for each single gene and with the exception of Vwf at 1 and 4 weeks after 
implantations, at each single observation point.
Endothelial differentiated ADSCs and osteogenic differentiated ADSCs can 
be simultaneously applied for the construction of ectopic osteogenic implants. 
A method of in vitro prevascularization applied by Zhang and his team included 
construction of double cell sheets (DCS) out of rabbit ADSCs previously in vitro 
induced into ECs and into osteogenic cells [110]. DCS were combined with coral 
hydroxyapatite (CHA) in four different manners. Twelve weeks after ectopic 
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implantation into nude mice, a group that contained CHA covered with DCS such 
that endothelial cell sheet was inside and osteogenic cell sheet outside exhibited the 
most favorable results regarding vascularization and bone maturation of the graft.
5.3.3 Co-cultivation
Co-cultivation of ECs with other cell types is one of the approaches for resolving 
the problem of inadequate vascularization in BTE [134]. ECs were co-cultivated with 
different types of cells before the implantation procedure, but the most important 
for BTE is co-cultivation of ECs and OBs since numerous interactions between these 
two cell types exist during normal bone regeneration process [130, 131]. One of the 
mechanisms of those interactions was found by Kaigler and associates [132]. They 
have shown that in vitro, ECs improve osteogenic capacity of bone mesenchymal 
stem cells (BMSCs) during co-cultivation, in direct contact or near each other. In 
part, this role of ECs could be attributed to release of BMP-2. In vivo, transplanted 
ECs enhanced capability of transplanted BMSCs to form the bones.
The positive effect of combination of ECs and OBs was estimated in ectopically 
implanted HA/bTCP scaffolds. The 3D porous ceramic scaffolds were seeded with 
in vitro co-cultivated ADSCs induced into OBs, ADSCs induced into ECs, and 
CD14+ osteoclast progenitors derived from human peripheral blood osteoclasts 
[133]. This three-dimensional organotypic culture model based on human cells 
was cultivated during 21 days in the perfusion bioreactor system. After cultivation, 
the system was implanted subcutaneously into dorsal pockets of nude mice. Eight 
weeks after implantation, blood vessels and bone-like tissue were formed.
In another study, co-cultivation of ADSCs induced into ECs and ADSCs induced 
into OBs did not have such positive effect on vascularization and osteogenic process 
[134]. Co-cultivation increased proliferation of this two cell types in vitro in com-
parison with monocultures or undifferentiated ADSCs. Nevertheless, co-cultures 
in a ratio 1:1 = OBs:ECs seeded on polylactic acid gas-plasma-treated scaffolds have 
not induced increased vascularization and signs of osteogenic process compared to 
the implants constituted out of non-induced ADSCs and polymer scaffolds. Unlike 
the co-culture group, ECs seeded on polymer scaffolds have increased vasculariza-
tion, and OBs seeded on polymer scaffolds have improved osteogenesis more than a 
group with undifferentiated ADSCs [134].
Unlike the results of the above discussed study, ADSCs in vitro induced into 
OBs and ADSCs in vitro induced into ECs and seeded into self-assembling peptide 
RADA16-I scaffolds as co-cultures (1:1) had better osteogeneration and vascular-
ization than the scaffolds seeded with monocultures of this type of cells or non-
induced ADSCs [135]. Before seeding the cells into RADA16-I scaffolds, it has been 
shown that the best interaction of ADSCs induced into OBs and ADSCs induced 
into ECs in co-cultures was achieved when the ratio of the cells was 1:1.
The results obtained by some of the abovementioned research teams, which 
were worse than expected regarding a group of implants that contained previously 
co-cultured ECs and OBs, could lie in the ratio of the applied cell types. It has been 
confirmed that application of too many ECs decreases graft neovascularization 
probably due to increase in metabolic load and enhanced competition for nutrients 
[136]. The other reason for those differences can be the differences in the applied 
biomaterials used for the implant construction [134].
5.3.4 Arteriovenous vascular bundle
Formation of arteriovenous vascular bundle (AVB) belongs to in vivo prevas-
cularization approaches. Incorporation of AVB into scaffolds represents a model 
17
Application of Adipose-Derived Stem Cells in Treatment of Bone Tissue Defects
DOI: http://dx.doi.org/10.5772/intechopen.92897
of scaffold that have artery and vein inserted into its central part. In this way, stem 
cells as well as cytokines, oxygen, and nutrients can be transported, while waste 
products can be removed from the scaffold. Altogether, that kind of construction 
leads to excellent vascularization and osteogenesis within the scaffold [137].
Scaffolds with AVB were combined with rat ADSCs previously subjected to 
in vitro endothelial differentiation. Obtained ECs were incorporated into porous 
nano-hydroxyapatite-polyamide 66 (nHA-PA 66) scaffolds in vitro [108]. After 
that, AV bundle was inserted into ECs-based nHA-PA 66 in vivo. Also, AV bundle 
was inserted into nHA-PA 66 scaffolds seeded with non-induced ADSCs and into 
empty nHA-PA 66 scaffolds, while one experimental group had nHA-PA 66 scaf-
folds without inserted AV bundle and without cells. Two and four weeks after the 
implantation procedure, the implants were extracted from the animals and ana-
lyzed. Density of blood vessels was significantly higher, and the diameter of blood 
vessels was larger in ECs-based nHA-PA 66 scaffolds than that in all other groups of 
implants.
5.3.5 Gene therapy
Combining ex vivo gene therapy with cell transplantation techniques that 
include endothelial cell line is another approach for overcoming the problem of 
insufficient vascularization in bone. The benefit of this method was assessed 
by using 3D poly (lactide-co-glycolide) sintered microsphere scaffolds in a BTE 
approach [138]. ADSCs were isolated from human infrapatellar fat tissue, and the 
cells were transfected with adenovirus that encodes cDNA of VEGF and combined 
with endothelial ones. As a result, genetically modified ADSCs combined with ECs 
caused prominent growth within 3D poly (lactide-co-glycolide) scaffolds, which 
indicates the potential for ADSCs application in improving vascularization in 
BTE. Another study where gene therapy and ADSCs were combined was conducted 
by Peterson and associates [139]. First, ADSCs were transfected with the BMP-2 
gene, then loaded on the collagen-ceramic carrier, and finally implanted in critical-
sized femoral defect of nude mice. Eight weeks after implantations, histologic, 
radiographic, and biomechanical analyses showed that the collagen-ceramic carrier 
combined with ADSCs previously transfected with the BMP-2 gene caused bone 
formation within the defect.
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